Detection of toxigenicClostridium difficilecolonization in patients admitted to the hospital for chemotherapy or haematopoietic cell transplantation. Issue 7 (July 2018)

• Record Type: Journal Article
• Authors: Vaughn, John L.; Balada‐Llasat, Joan‐Miquel; Lamprecht, Misty; Huang, Ying; Anghelina, Mirela; El Boghdadly, Zeinab; Bishop‐Hill, Karen; Childs, Rachel; Pancholi, Preeti; Andritsos, Leslie A.
• Is Part Of: Journal of medical microbiology. Volume 67:Issue 7(2018)
• Publication Date: 2018-07
• Subjects: Clostridium difficile -- chemotherapy -- haematopoietic cell transplantation -- colonization; Medical microbiology -- Periodicals; 616.9041
• DOI: 10.1099/jmm.0.000774
• Languages: English
• ISSNs: 0022-2615

Abstract

Abstract : N/A: Increasing evidence suggests that asymptomatic carriers are an important source of healthcare‐associated Clostridium difficile infection. However, it is not known which test for the detection of C. difficile colonization is most sensitive in patients with haematological malignancies. We performed a prospective cohort study of 101 patients with haematological malignancies who had been admitted to the hospital for scheduled chemotherapy or haematopoietic cell transplantation. Each patient provided a formed stool sample. We compared the performance of five different commercially available assays, using toxigenic culture as the reference method. The prevalence of toxigenic C. difficile colonization as determined by toxigenic culture was 14/101 (14 %). The Cepheid Xpert PCR C. difficile /Epi was the most sensitive test for the detection of toxigenic C. difficile colonization, with 93 % sensitivity and 99 % negative predictive value. Our findings suggest that the Xpert PCR C. difficile /Epi could be used to rule out toxigenic C. difficile colonization in this population.